Abstract:Background: Non-motor symptoms (NMS) are compulsory clinical features for the clinical diagnosis of multiple system atrophy (MSA), some of which precede motor symptoms onset. To date, few studies have systematically investigated NMS in MSA and the timing of presenting NMS as the disease progresses. Clinically, MSA is difficult to be differentiated from Parkinson's disease (PD) and progressive supranuclear palsy (PSP), and the differences in NMS between MSA and PD/PSP remain unclear. The aim of this study was to compare the burden of NMS between MSA and PD/PSP and to delineate the timing of NMS presentation relative to the onset of motor symptoms in MSA. Methods: A total of 61, 87, and 30 patients with MSA, PD, and PSP, respectively, were enrolled in this study. NMS was systematically assessed in all patients using the NMS scale (NMSS), and the onset of NMS relative to the onset of motor symptoms in MSA was investigated. Results: MSA group had higher total NMSS scores (82.15 ± 46.10) than the PD (36.14 ± 30.78) and PSP (50.30 ± 55.05) groups ( p < 0.001 overall). The number distribution pattern of the NMS was significantly different among the three parkinsonian disorders ( p < 0.001 overall). In total, 85.2% of patients with MSA had more than 10 NMS, which was significantly higher than PD (28.7%) and PSP (33.3%). The frequency and scores of many NMSS subdomains and symptoms were higher in MSA than in PD and PSP (all p < 0.05). Multivariate logistic regression analysis revealed that patients with fainting, lack of motivation, swallowing, and loss of sexual interest could be attributed to MSA rather than PD or PSP, while patients with loss of concentration and forgetfulness were characteristic features of PD or PSP rather than MSA. REM-sleep behavior disorder (RBD), constipation, problems having sex, and loss of sexual interest preceded the motor symptoms onset of MSA by 2.81 ± 4.51, 1.54 ± 6.32, 1.35 ± 4.70, and 0.45 ± 3.61 years, respectively. Conclusion: The NMS spectrum in MSA differs from that of PD and PSP. Patients with MSA have a higher NMS burden than patients with PD or PSP. RBD, constipation, problems having sex, and loss of sexual interest may become early diagnostic clinical markers of MSA.

Support needs of people with multiple system atrophy

End-of-life care in multiple system atrophy: UK survey of patients and families

Health-Related Quality of Life in Multiple System Atrophy Using EQ-5D-5L: A Large Cross-Sectional Study in China

Non-motor symptoms in multiple system atrophy: A comparative study with Parkinson's disease and progressive supranuclear palsy

Non-motor Symptoms and the Quality of Life in Multiple System Atrophy with Different Subtypes.

Health-related quality of life in patients with multiple system atrophy using the EQ-5D-5L

The Palliative Care Needs of Patients with Multiple Sclerosis, Parkinson's Related Diseases, and Motor Neurone Disease: A Secondary Analysis of the OPTCARE Neuro Trial Data

Prevalence of and Factors Associated with Postural Deformities in Chinese Patients with Multiple System Atrophy

Clinical Characteristics and Quality of Life in Chinese Patients with Multiple System Atrophy.

The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis

Fatigue Prevalence and Associated Factors in Patients with Multiple System Atrophy

Fatigue in Patients With Multiple System Atrophy A Prospective Cohort Study

Depression and Anxiety in Multiple System Atrophy.

In Vivo Cerebral Metabolic and Dopaminergic Characteristics in Multiple System Atrophy with Orthostatic Hypotension.

A Review on the Clinical Diagnosis of Multiple System Atrophy

Multiple System Atrophy: Recent Developments and Future Perspectives

Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions

The Importance of Connection to Others in QoL in MSA and PSP

Orthostatic Hypotension in Multiple System Atrophy: Related Factors and Disease Prognosis.

Sleep-related symptoms in multiple system atrophy: determinants and impact on disease severity